| Nov 18 |
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
|
| Nov 15 |
Silo Pharma Third Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.21 loss in 3Q 2023)
|
| Oct 31 |
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
|
| Sep 10 |
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
|
| Aug 21 |
Silo Pharma files for secondary stock offering
|
| Aug 14 |
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
|
| Aug 7 |
Silo Pharma announces partnership with global CRO for central nervous system homing peptide
|
| Aug 7 |
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
|
| Jul 26 |
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
|
| Jul 22 |
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
